GlycoMimeticsGLYC
About: GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Employees: 35
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
9% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 11
3% less funds holding
Funds holding: 35 [Q2] → 34 (-1) [Q3]
12.12% less ownership
Funds ownership: 39.66% [Q2] → 27.54% (-12.12%) [Q3]
58% less capital invested
Capital invested by funds: $7.2M [Q2] → $3M (-$4.2M) [Q3]
77% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 13
Research analyst outlook
We haven’t received any recent analyst ratings for GLYC.
Financial journalist opinion
Based on 10 articles about GLYC published over the past 30 days
